Flynn James E Sample Contracts
DEERFIELD CAPITAL, L.P.Joint Filing Agreement • September 23rd, 2008 • Flynn James E • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Nitromed, Inc. and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.
JOINT FILING AGREEMENTJoint Filing Agreement • October 19th, 2009 • Flynn James E • Pharmaceutical preparations
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the Common Stock of Hana Biosciences, Inc. and that this Agreement be included as an Exhibit to such joint filing. This Agreement may be executed in any number of counterparts all of which taken together shall constitute one and the same instrument.
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 8th, 2020 • Flynn James E • Pharmaceutical preparations • Delaware
THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of June 8, 2020 (the “Effective Date”), is made and entered into by and among Larimar Therapeutics, Inc., a Delaware corporation (f/k/a Zafgen, Inc.) (the “Company”), and each of the investors set forth on the signature pages hereto (each, an “Investor” collectively, the “Investors”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 15th, 2012 • Flynn James E • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of March 13, 2012 by and among Flamel Technologies, S.A., a société anonyme under the laws of the Republic of France (the “Company”), and Éclat Holdings, LLC (the “Buyer”).
INVESTMENT AGREEMENT dated as of June 24, 2020 by and between ADAPTHEALTH CORP. and DEERFIELD PARTNERS, L.P.Investment Agreement • June 25th, 2020 • Flynn James E • Services-home health care services • Delaware
INVESTMENT AGREEMENT, dated as of June 24, 2020 (this “Agreement”), by and between AdaptHealth Corp., a Delaware corporation (the “Company”), and Deerfield Partners, L.P., a Delaware limited partnership (the “Purchaser”).
LIMITED LIABILITY COMPANY AGREEMENT OF DEERFIELD/RAB VENTURES, LLCLimited Liability Company Agreement • March 5th, 2018 • Flynn James E • Blank checks • Delaware
This Limited Liability Company Agreement (this “Agreement”) of Deerfield/RAB Ventures, LLC, a Delaware limited liability company (“the “Company”), is entered into and made effective as of February 15, 2018, by and among the members of the Company set forth on Schedule I attached hereto (individually, a “Member” and, collectively, the “Members”).
WAIVER AGREEMENTWaiver Agreement • July 18th, 2013 • Flynn James E • Pharmaceutical preparations • Delaware
THIS WAIVER AGREEMENT (this “Agreement”) is entered into as of July 16, 2013 by and among Talon Therapeutics, Inc., a Delaware corporation (the “Company”), and the undersigned stockholders of the Company (the “Stockholders” and together with the Company, the “Parties”).
SECURITIES PURCHASE AGREEMENT by and among SPECTRUM PHARMACEUTICALS, INC. EAGLE ACQUISITION MERGER SUB, INC. and THE SECURITYHOLDERS OF TALON THERAPEUTICS, INC. NAMED HEREIN JULY 16, 2013Securities Purchase Agreement • July 18th, 2013 • Flynn James E • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of July 16, 2013, by and among Spectrum Pharmaceuticals, Inc., a Delaware corporation (“Parent”), Eagle Acquisition Sub, Inc., a Delaware corporation (“Purchaser”), Warburg Pincus Private Equity X, L.P. (“WPX”), Warburg Pincus X Partners, L.P. (“WPPX” and, together with WPX, the “WP Entities”), Deerfield Private Design Fund, L.P. (“Deerfield Private Design Fund”), Deerfield Special Situations Fund, L.P. (“Deerfield Special Situations Fund”), Deerfield Special Situations Fund International Limited (“Deerfield International”) and Deerfield Private Design International, L.P. (“Deerfield Private Design International” and, together with Deerfield Private Design Fund, Deerfield Special Situation Fund and Deerfield International, the “Deerfield Entities”). The WP Entities and the Deerfield Entities shall be referred to herein individually as “Seller” and collectively as “Sellers.”
ADAPTHEALTH CORP.Investment Agreement • May 26th, 2020 • Flynn James E • Services-home health care services • Delaware
Reference is made to (i) that certain Investment Agreement (the “Third Party Investment Agreement”), dated as of the date hereof, between AdaptHealth Corp. (the “Company”), OEP AHCO Investment Holdings, LLC (“OEP Vehicle”) and, for the purposes of Section 3.10 thereof, One Equity Partners VII, L.P. (“OEP Fund” and, together with OEP Vehicle, “One Equity”), (ii) the form of Certificate of Designations (as defined in the Third Party Investment Agreement) attached as an exhibit to the Third Party Investment Agreement and (iii) the Voting Agreement (the “Voting Agreement”), dated as of the date hereof, between the Company and Deerfield Private Design Fund IV, L.P. (“DPDIV”). For good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, DPDIV, Deerfield Partners, L.P. (“Deerfield Partners”, and together with DPDIV, “Deerfield”) and the Company hereby agree as follows:
Joint Filing AgreementJoint Filing Agreement • November 13th, 2025 • Flynn James E • Services-home health care services
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Class A common stock of AdaptHealth Corp. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • August 18th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of BridgeBio Oncology Therapeutics, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • February 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Class A common stock, $0.0001 par value per share, of Nuvalent, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • February 13th, 2025 • Flynn James E • Services-health services
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of DocGo Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • February 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Catalyst Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • November 13th, 2025 • Flynn James E • Services-prepackaged software
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Certara, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • November 13th, 2025 • Flynn James E • Biological products, (no disgnostic substances)
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Cullinan Therapeutics, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • September 19th, 2016 • Flynn James E • Services-hospitals
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Adeptus Health Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.
Joint Filing AgreementJoint Filing Agreement • November 25th, 2025 • Flynn James E • Services-prepackaged software
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Certara, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • February 12th, 2026 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Class A common stock, $0.0001 par value per share, of Nuvalent, Inc. shall be filed on behalf of the undersigned.
Exhibit A Joint Filing AgreementJoint Filing Agreement • February 6th, 2026 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of CalciMedica Inc. shall be filed on behalf of the undersigned.
JOINT FILING AGREEMENTJoint Filing Agreement • March 23rd, 2020 • Flynn James E • Blank checks
Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder (the “Exchange Act”) the undersigned hereby agree to the joint filing on behalf of each of them of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, restatement, supplement, and/or exhibit thereto) with respect to securities of DFP Healthcare Acquisitions Corp., a Delaware corporation, and further agree to the filing, furnishing, and/or incorporation by reference of this Agreement as an exhibit thereto. Each of them is responsible for the timely filing of such filings and any amendments thereto, and for the completeness and accuracy of the information concerning such person contained therein; but none of them is responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such
Joint Filing AgreementJoint Filing Agreement • August 14th, 2025 • Flynn James E • Services-nursing & personal care facilities
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Brookdale Senior Living Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • May 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Ordinary Shares of Mallinckrodt plc shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • June 29th, 2017 • Flynn James E • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Proteon Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.
Joint Filing AgreementJoint Filing Agreement • February 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Kura Oncology, Inc. shall be filed on behalf of the undersigned.
VOTING AGREEMENTVoting Agreement • May 26th, 2020 • Flynn James E • Services-home health care services • Delaware
This Voting Agreement (this “Agreement”), dated as of May 25, 2020 between AdaptHealth Corp., a Delaware corporation (the “Company”), and the undersigned stockholder of the Company (“Stockholder”).
JOINDER TO LETTER AGREEMENTJoinder Agreement • January 24th, 2020 • Flynn James E • Services-home health care services • New York
THIS JOINDER AGREEMENT (the “Joinder”) to that certain Letter Agreement (the “Insider Letter”), dated February 15, 2018, by and among AdaptHealth Corp. (formerly known as DFB Healthcare Acquisitions Corp.), a Delaware corporation (the “Company”), Deerfield/RAB Ventures, LLC, a Delaware limited liability company (the “Sponsor”), Richard Barasch, Christopher Wolfe, Steven Hochberg, Dr. Mohit Kaushal, Dr. Gregory Sorensen and Dr. Susan Weaver, is hereby made by RAB Ventures (DFB) LLC and Deerfield Private Design Fund IV, L.P., and is being entered in connection with the dissolution of the Sponsor. Capitalized terms used but not otherwise defined herein shall have the meanings set forth in the Insider Letter.
Exhibit A Joint Filing AgreementJoint Filing Agreement • November 13th, 2025 • Flynn James E • Hospital & medical service plans
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Oscar Health, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • May 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Ordinary Shares, $0.50 nominal value per share of Indivior PLC shall be filed on behalf of the undersigned.
Agreement The undersigned agree that this Schedule 13G and all amendments thereto, relating to the Common Stock of ARENA PHARMACEUTICALS, INC. shall be filed on behalf of the undersigned. DEERFIELD CAPITAL, L.P. By: J.E. Flynn Capital LLC, General...Schedule 13g • October 23rd, 2007 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G and all amendments thereto, relating to the Common Stock of ARENA PHARMACEUTICALS, INC. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • May 13th, 2025 • Flynn James E • Surgical & medical instruments & apparatus
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Embecta Corp. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • February 12th, 2026 • Flynn James E • Biological products, (no disgnostic substances)
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of BioCryst Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.
AMENDMENT TO REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 25th, 2020 • Flynn James E • Services-home health care services • Delaware
This AMENDMENT TO REGISTRATION RIGHTS AGREEMENT (this “Amendment”) is made as of June 24, 2020 (the “Amendment Date”) and amends that certain Registration Rights Agreement, dated as of November 8, 2019 (the “Original Agreement”), by and among AdaptHealth Corp., a Delaware corporation (“Pubco”), and certain of its shareholders party thereto (each a “Investor” and, collectively, the “Investors”). Capitalized terms used but not otherwise defined herein are defined in the Original Agreement.
Joint Filing AgreementJoint Filing Agreement • November 13th, 2025 • Flynn James E • Pharmaceutical preparations
The undersigned agree that this Schedule 13G, and all amendments thereto, relating to the Common Stock of Lomond Therapeutics Holdings, Inc. shall be filed on behalf of the undersigned.
Joint Filing AgreementJoint Filing Agreement • August 4th, 2017 • Flynn James E • Biological products, (no disgnostic substances)
In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the common stock of Proteon Therapeutics, Inc. and further agree that this Joint Filing Agreement be included as an Exhibit to such joint filings.